<!DOCTYPE html>
<html>
<head>
    <title>PressReader - The Straits Times: 2020-08-11 - Lo&#xAD;cal biotech firm do&#xAD;ing Covid-19 re&#xAD;search gets $15m fund in&#xAD;jec&#xAD;tion</title>
    <meta name="description" content="Sum will boost its im&#xAD;mune pro&#xAD;fil&#xAD;ing tech that is key to de&#xAD;vel&#xAD;op&#xAD;ing vac&#xAD;cines and treat&#xAD;ment">
    <meta content="magazines, newspapers, digital news, reading, news, breaking news, newspaper online" name="keywords">
    <meta name="Robots" content="NOARCHIVE,NOODP">
    <meta charset="UTF-8">
    <meta http-equiv="Content-type" content="text/html; charset=utf-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1" />
    
    <link rel="canonical" href="/singapore/the-straits-times/20200811/281719796935863" />


    <style>
        li {
            margin: 1em 0;
        }
        img {
            max-width: 100%;
        }
        p, h1, h2, h3 {
            max-width: 100%;
        }
    </style>
</head>
<body>
    <div>
        

<article>
    <h1>Lo&#xAD;cal biotech firm do&#xAD;ing Covid-19 re&#xAD;search gets $15m fund in&#xAD;jec&#xAD;tion</h1>
    <h2>Sum will boost its im&#xAD;mune pro&#xAD;fil&#xAD;ing tech that is key to de&#xAD;vel&#xAD;op&#xAD;ing vac&#xAD;cines and treat&#xAD;ment</h2>
    <section>
        <a href="/singapore/the-straits-times/textview" title="The Straits Times">The Straits Times</a>
        - <a href="/singapore/the-straits-times/20200811/textview" title="The Straits Times - 2020-08-11"><time>2020-08-11</time></a>
        - <span>TOP OF THE NEWS</span>
        - <span role="byline">Clara Chong chongcjy@sph.com.sg</span>
    </section>

    <p>A lo­cal biotech­nol­ogy firm in­volved in Covid-19 re­search has raised US$11 mil­lion (S$15 mil­lion) from in­ter­na­tional in­vestors to ex­pand its op­er­a­tions and en­hance its tech­nol­ogy in im­mune pro­fil­ing.</p>
    <p>The sig­nif­i­cant fund in­jec­tion will sup­port the mul­ti­ple projects that Im­munoS­cape, a spin-off from the Agency for Science, Tech­nol­ogy and Re­search (A*Star) which started op­er­a­tions in 2017, is work­ing on.</p>
    <p>A key project is part­ner­ing vaccine de­vel­op­ment firms and re­search groups to an­a­lyse the body’s im­mune re­sponses to the coro­n­avirus.</p>
    <p>Im­munoS­cape is also do­ing re­search in im­muno-on­col­ogy, aimed at de­vel­op­ing treat­ments that use the body’s im­mune sys­tem to fight cancer.</p>
    <p>The two main in­vestors are USbased ven­ture firm Anzu Part­ners, which in­vested US$6 mil­lion, and the Univer­sity of Tokyo Edge Cap­i­tal (Utec) in Ja­pan, which in­vested US$2.65 mil­lion. Other in­vestors con­trib­uted the re­main­ing sum.</p>
    <p>Dr Alessandra Nardin, chief op­er­at­ing of­fi­cer of Im­munoS­cape, said the team has de­vel­oped an im­mune pro­fil­ing plat­form that could be lever­aged for vaccine de­sign.</p>
    <p>Work­ing with Covid-19 pa­tients and re­cov­ered in­di­vid­u­als, the firm is gath­er­ing a large data set on the hu­man T-cell re­sponse to the virus. The T cell is a type of white blood cell that makes up part of an im­mune re­sponse. The aim is to de­velop treat­ment and vac­cines with its part­ners, Dr Nardin said.</p>
    <p>Im­munoS­cape has links with Mas­sachusetts Gen­eral Hospi­tal in the United States, the Univer­sity of Parma in Italy and Duke-NUS Med­i­cal School in Sin­ga­pore.</p>
    <p>To battle Covid-19, Im­munoS­cape has col­lab­o­rated with var­i­ous vaccine de­vel­op­ment firms, such as the US’ Arc­turus Ther­a­peu­tics, which is run­ning clin­i­cal tri­als in Sin­ga­pore.</p>
    <p>Mr Ng Choon Peng, chief ex­ec­u­tive of Im­munoS­cape, said it plans to bring in ad­di­tional man­power, such as im­mu­nol­o­gists, bioin­for­mati­cians and spe­cial­ists, for its lab­o­ra­tory at Sin­ga­pore re­search and de­vel­op­ment hub Biopo­lis.</p>
    <p>“We are ex­pand­ing into key mar­kets like the US and Ja­pan, build­ing a busi­ness de­vel­op­ment team, as well as a lab in the US,” he said.</p>
    <p>Mr Ng hopes to even­tu­ally be able to use ma­chine learn­ing and ar­ti­fi­cial in­tel­li­gence (AI) ca­pa­bil­i­ties to un­cover more in­sights into the im­mune sys­tem.</p>
    <p>As more data is col­lected over time, AI is needed to an­a­lyse and process the data to de­ci­pher more pat­terns that might emerge, he said.</p>
    <p>This will aid Im­munoS­cape’s cur­rent part­ner­ships with drug de­vel­op­ment com­pa­nies to de­velop their cancer and Covid-19 drugs more quickly and in­crease the suc­cess rates of clin­i­cal tri­als.</p>
    <p>Im­munoS­cape also hopes to con­tinue its core work: En­abling ad­vanced im­munother­a­pies for cancer. By analysing ev­ery pa­tient’s unique im­mune sys­tem, it would help the bio­phar­ma­ceu­ti­cal sec­tor to de­velop in­di­vid­u­alised medicine for cancer.</p>
    <p>This is some­thing Anzu Part­ners is keen to sup­port, said its man­ag­ing part­ner David Michael.</p>
    <p>Im­munoS­cape’s suc­cess in se­cur­ing crit­i­cal fund­ing came af­ter A*ccel­er­ate, the com­mer­cial­i­sa­tion arm of A*Star, in­tro­duced the com­pany to Utec and Anzu Part­ners dur­ing a visit to Sin­ga­pore by the two ven­ture cap­i­tal firms.</p>
    <p>Anzu Part­ners, which is in­vest­ing in Im­munoS­cape for the first time, be­lieves the com­pany has de­vel­oped a valu­able and dif­fer­en­ti­ated ca­pa­bil­ity of pro­fil­ing the im­mune sys­tem.</p>
    <p>“We ex­pect the com­pany man­age­ment to wisely use the funds to de­velop their com­mer­cial ca­pa­bil­i­ties into global bio­pharma mar­kets,” said Mr Michael.</p>
    <p>Utec, on the other hand, has pre­vi­ously in­vested $2.4 mil­lion in the Sin­ga­pore com­pany as it saw the tremen­dous value and po­ten­tial, it said, adding that it does not rule out fur­ther in­vest­ments.</p>
    <p>Utec part­ner Naonori Kurokawa said: “The abil­ity to dis­cover mul­ti­ple T-cell anti­gens from pa­tients is game-chang­ing and can pro­vide valu­able and crit­i­cal in­for­ma­tion to biotech com­pa­nies de­vel­op­ing cancer im­munother­apy.”</p>
    <p>How T cells fight viruses</p>
    <p>When the body is un­der threat, cells are ac­ti­vated to launch a coun­ter­at­tack. Clara Chong looks at the science be­hind it.</p>

    <div>
        <picture>
            <img src="https://i.prcdn.co/img?regionKey=aTURlWPl6pQ63BrNg1S3sA%3d%3d" />
        </picture>
        <span role="byline">PHOTOS: IM&#xAD;MUNOS&#xAD;CAPE</span>
        <p data-role="text">Im&#xAD;munoS&#xAD;cape&#x2019;s op&#xAD;er&#xAD;a&#xAD;tions and de&#xAD;vel&#xAD;op&#xAD;ment team at its lab&#xAD;o&#xAD;ra&#xAD;tory in Biopo&#xAD;lis. The $15 mil&#xAD;lion fund in&#xAD;jec&#xAD;tion will sup&#xAD;port the com&#xAD;pany&#x2019;s mul&#xAD;ti&#xAD;ple projects, a key one be&#xAD;ing part&#xAD;ner&#xAD;ing vaccine de&#xAD;vel&#xAD;op&#xAD;ment firms and re&#xAD;search groups to an&#xAD;a&#xAD;lyse the body&#x2019;s im&#xAD;mune re&#xAD;sponses to the coro&#xAD;n&#xAD;avirus.</p>
    </div>
    <div>
        <picture>
            <img src="https://i.prcdn.co/img?regionKey=iNgahE%2bzCW6iYlyghS9v1g%3d%3d" />
        </picture>
        <span role="byline"></span>
        <p data-role="text">(From left) Im&#xAD;munoS&#xAD;cape ad&#xAD;viser Evan Newell, chief op&#xAD;er&#xAD;at&#xAD;ing of&#xAD;fi&#xAD;cer Alessandra Nardin, chief ex&#xAD;ec&#xAD;u&#xAD;tive of&#xAD;fi&#xAD;cer Ng Choon Peng and di&#xAD;rec&#xAD;tor of sci&#xAD;en&#xAD;tific af&#xAD;fairs Michael Fehlings. The com&#xAD;pany, a spin-off from the Agency for Science, Tech&#xAD;nol&#xAD;ogy and Re&#xAD;search, started op&#xAD;er&#xAD;a&#xAD;tions in 2017.</p>
    </div>

</article>

<section>
    <h3><a href="/catalog/language/english">Newspapers in English</a></h3>
    <h3><a href="/catalog/country/singapore">Newspapers from Singapore</a></h3>
</section>

    </div>
    
    <p><a href="http://www.pressreader.com">© PressReader. All rights reserved.</a></p>

        <script>
            (function (i, s, o, g, r, a, m) {
                i['GoogleAnalyticsObject'] = r; i[r] = i[r] || function () {
                    (i[r].q = i[r].q || []).push(arguments);
                }, i[r].l = 1 * new Date();
                a = s.createElement(o), m = s.getElementsByTagName(o)[0]; a.async = 1; a.src = g;
                m.parentNode.insertBefore(a, m);
            })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
        </script>
        <script>
            ga('create', 'UA-44408245-1');
            ga('send', 'pageView');
        </script>
</body>
</html>
